Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

http://www.wikidata.org/entity/Q33370390

about

Pancreatic cancer: New hopes after first line treatment Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Overcoming drug resistance in pancreatic cancer.Systemic therapy for metastatic pancreatic adenocarcinoma.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Gemcitabine in the treatment of metastatic pancreatic cancer.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Lentivirus-mediated overexpression of TGF-β inducible early gene 1 inhibits SW1990 pancreatic cancer cell growth.Role of taxanes in pancreatic cancer.Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma.Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

P2860

Q28067055-9621B422-044D-475D-8848-9F6DC1B6C854 Q33382236-781498DB-CE61-4512-89B6-35D09F7226CA Q33394190-B1ECB8C4-3C2F-4DF9-A559-20FAC2F9B31F Q33394729-0F22D7E6-DE2D-4592-8A73-9BC3BCF077A3 Q33428382-23A3E703-7CFF-4268-AAA3-4FA7E7C04D4E Q33751227-276B2F85-C766-43F7-91C1-D18AEA8E6C90 Q33778296-B60BD8D8-10A0-4700-8073-39138B60F184 Q33823212-6D0EAF40-F9BF-4487-BD0D-EA86C2F3E077 Q34308370-0A0C7EC0-D2EB-4AB1-A6F4-5CCF7FA640FA Q35036615-A7BAF418-E396-4ACB-86DD-1E4B6F5ED966 Q35076238-6132FB2F-F380-40C5-BA48-EE6F286C1A70 Q36610441-9BB9C437-DD87-41BB-A7C1-038AA72879DA Q37032865-52A2E0CA-F728-4ACA-8B42-14389F3D75E8 Q37074126-52F5B8B1-238F-4CFF-B3A7-95570C3781C1 Q37134412-21138A11-0237-48D7-B25E-8CC159163CBE Q37617955-07D0EAB8-A912-4D57-9095-84356E997D60 Q38577917-4F0F6115-C97A-4F86-9E47-F8BACC0E210B Q39552151-5FCA9D7B-D7C8-481C-B9A7-4767232671CD Q42323567-DB441767-4CD2-4565-B3C7-1CBDD627F6FB Q42959222-BF7EAC99-1BB3-4B0D-948B-16A02AD1A350 Q43147217-B213FFBF-1361-490D-8876-82BDDFC84409 Q44916594-F0FB0E3B-1EFA-4A3D-98B5-8E0AC48EB5D5 Q48825323-2D692D73-66C6-4CA8-914A-DCCDCE463D2F Q53561339-F2BBD2C0-295A-4824-B900-D3C721538190 Q55223567-A757B1EA-1AD6-4559-A277-C92D26798A7F Q58799265-462C0602-9E24-4383-B064-15E1C773678E

P2860

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

http://www.wikidata.org/entity/Q33370390

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@ast

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@en

type

label

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@ast

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@en

prefLabel

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@ast

Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.

@en

P1433

Q33370390-64D52337-A07C-4E58-9689-273B1B7DAF13

P1476

Q33370390-D5532480-7F27-42AE-B8D9-EA6439B0F714

P2093

Q33370390-02B715F0-C443-4448-AD1C-5B290E5716D8

Q33370390-2CCC040C-6AE7-4040-9040-BE2DE9453E3B

Q33370390-36872528-91DA-4D3F-AB5D-EAB20A83F76D

Q33370390-38CD5DB8-84A7-4B8C-975D-DCB82F23EE2C

Q33370390-59A3E5E2-F072-446B-82A5-F319DDB599A8

Q33370390-626AD1AA-7EA3-4D45-92EB-9B93DBB2B886

Q33370390-6A291F79-6994-4BF5-B6FD-3FDECE3209B6

Q33370390-8E630A54-B5C1-4635-BDB4-509F5B1A0A9E

Q33370390-AAC3810C-8CB3-4840-924B-2AFC0999D1F3

Q33370390-BBBE790B-6479-4DC4-AE23-15E69F147C3F

P2860

Q33370390-0331CD65-BD3C-4758-B85A-DCCEACB73510

Q33370390-126C1C41-C59D-4322-A498-C78D3473FA17

Q33370390-17514D6F-E3A6-4438-863F-4C4871C62AA3

Q33370390-23589E59-3106-4889-AE94-B1AF998A05D1

Q33370390-2C6FF491-4A61-44B9-888C-7448F20FBC64

Q33370390-2DFE0C10-75D1-476D-A87F-2ADE451F4DE1

Q33370390-491532E4-3A2E-4773-93E0-3BB824E05C62

Q33370390-50A542F4-DBD0-4E96-901C-FC2D4A81178E

Q33370390-52141995-E6DC-4212-90AF-1F0936B0254E

Q33370390-649F4F6D-2D5F-41F8-ADA8-D31E4FAE1B40

P2888

Q33370390-41DA3ED1-E379-4DA7-B330-0EBEBD7DEDE5

P304

Q33370390-251A4510-237B-4BE2-8FE2-2CEBF7D94BCA

P31

Q33370390-B300F9A9-158D-492E-A998-BA3A11B516B5

P356

Q33370390-47FAD564-A7D0-409F-9D07-344AAAFE2FD2

P407

Q33370390-792F8CC1-DD99-45AC-9B51-A1A5C4492624

P433

Q33370390-7AA8E677-A3D4-4F62-AB8D-C8C93F803EB4

P478

Q33370390-014780E3-5B58-40A0-ACAF-9EC63BA17D3F

P50

Q33370390-1380CF80-3104-4E9F-A588-3A0FF4F4D6CA

Q33370390-FBC8E1E0-E6DA-4F82-B24B-89A512BBDB29

P577

Q33370390-37DC391A-6078-46EE-A8D2-42A360083400

P5875

Q33370390-2A57906A-DB3B-4AE4-9114-D225838F5992

P6179

Q33370390-FBB8C128-5D67-469D-BC8A-9346AE2A4E9A

P698

Q33370390-B6A56733-C756-44B5-9CCC-55EC69994B47

P921

Q33370390-64615329-40BD-4FD3-BA44-71E67BE99853

P932

Q33370390-24561B38-3022-4770-8D06-BC726FC60A9E

P356

P1433

British Journal of Cancer

P1476

Raltitrexed-eloxatin salvage c ...... t metastatic pancreatic cancer

@en

P2093

A Zerbi

http://www.w3.org/2001/XMLSchema#string

C Fugazza

http://www.w3.org/2001/XMLSchema#string

C Milandri

http://www.w3.org/2001/XMLSchema#string

E Bonetto

http://www.w3.org/2001/XMLSchema#string

G Aprile

http://www.w3.org/2001/XMLSchema#string

G Balzano

http://www.w3.org/2001/XMLSchema#string

G Luppi

http://www.w3.org/2001/XMLSchema#string

L Pasetto

http://www.w3.org/2001/XMLSchema#string

M Reni

http://www.w3.org/2001/XMLSchema#string

P Passoni

http://www.w3.org/2001/XMLSchema#string

P2860

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

P2888

P304

785-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603026

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Piemonti

Alba A. Brandes

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7268450

http://www.w3.org/2001/XMLSchema#string

P6179

1028056239

http://www.w3.org/2001/XMLSchema#string

P698

16508631

http://www.w3.org/2001/XMLSchema#string

P921

P932

2361378

http://www.w3.org/2001/XMLSchema#string